Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hutchmed (HCM) Share Price

Price 214.00p on 06-03-2026 at 19:30:06
Change 12.00p 5.94%
Buy 213.00p
Sell 210.00p
Last Trade: Sell 881.00 at 214.00p
Day's Volume: 40,131
Last Close: 214.00p
Open: 200.00p
ISIN: KYG4672N1198
Day's Range 200.00p - 214.00p
52wk Range: 187.50p - 292.00p
Market Capitalisation: £1.84b
VWAP: 207.03825p
Shares in Issue: 859.52m

Hutchmed (HCM) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 881 214.00p Automatic Execution
16:35:27 - 06-Mar-26
Sell* 3,110 214.00p Uncrossing Trade
16:35:17 - 06-Mar-26
Sell* 860 210.00p Automatic Execution
16:26:04 - 06-Mar-26
Sell* 200 210.00p Automatic Execution
16:25:36 - 06-Mar-26
Sell* 137 210.00p Automatic Execution
16:25:36 - 06-Mar-26
Sell* 63 210.00p Automatic Execution
16:25:36 - 06-Mar-26
Sell* 430 210.00p Automatic Execution
16:19:17 - 06-Mar-26
Sell* 250 210.00p Automatic Execution
16:19:17 - 06-Mar-26
Sell* 300 210.00p Automatic Execution
16:19:17 - 06-Mar-26
Sell* 174 210.00p Automatic Execution
16:19:17 - 06-Mar-26
See more Hutchmed trades

Hutchmed (HCM) Share Price History

Time period:
to
Date Open High Low Close Volume
6th Mar 2026 (Fri) 200.00 214.00 200.00 214.00 40,131
5th Mar 2026 (Thu) 210.00 210.00 199.00 202.00 10,900
4th Mar 2026 (Wed) 202.00 206.00 202.00 206.00 7,299
3rd Mar 2026 (Tue) 210.00 210.00 198.50 203.25 4,903
2nd Mar 2026 (Mon) 210.00 210.00 201.00 205.00 1,314
27th Feb 2026 (Fri) 220.00 220.00 215.00 215.00 21,341
26th Feb 2026 (Thu) 219.00 220.00 219.00 220.00 54,359
25th Feb 2026 (Wed) 219.00 220.00 219.00 220.00 2,120
24th Feb 2026 (Tue) 211.00 211.00 210.00 210.00 14,085
23rd Feb 2026 (Mon) 220.00 225.00 209.00 222.00 63,040
20th Feb 2026 (Fri) 208.00 221.00 208.00 220.00 561
19th Feb 2026 (Thu) 220.00 221.00 217.00 220.00 58,192
18th Feb 2026 (Wed) 218.00 220.00 205.00 220.00 14,040
17th Feb 2026 (Tue) 211.00 221.00 211.00 214.00 11,329
16th Feb 2026 (Mon) 215.00 215.00 212.50 212.50 4,270
13th Feb 2026 (Fri) 209.00 215.00 209.00 215.00 10,803
12th Feb 2026 (Thu) 214.00 214.00 214.00 214.00 4,282
11th Feb 2026 (Wed) 216.00 220.00 215.00 219.00 23,843
10th Feb 2026 (Tue) 216.00 220.00 215.00 219.00 10,740
9th Feb 2026 (Mon) 215.00 216.00 212.00 212.00 220,473
See more Hutchmed price history

Hutchmed (HCM) Regulatory News

Date Source Headline
6th Mar 2026 8:30 am RNS Directorate change
5th Mar 2026 1:00 pm RNS-R Publication of Form 20-F
5th Mar 2026 11:00 am RNS 2025 Full Year Results and Business Updates
4th Mar 2026 8:30 am RNS-R HUTCHMED Initiates Global Trial of ATTC Candidate
6th Feb 2026 8:30 am RNS HUTCHMED to Announce 2025 Final Results
14th Jan 2026 7:00 am RNS-R Publication of Phase III Results in The Lancet
7th Jan 2026 7:00 am RNS-R Positive Topline Results of Phase III Trial
5th Jan 2026 7:00 am RNS-R Surufatinib + Camrelizumab PDAC Phase 3 initiation
31st Dec 2025 7:00 am RNS Total Voting Rights
31st Dec 2025 7:00 am RNS Total Voting Rights
See more Hutchmed regulatory news

Hutchmed (HCM) Share News

Hutchmed China 2025 profit surges on divestment but revenue falls

5th Mar 2026 11:43

(Alliance News) - Hutchmed China Ltd on Thursday reported lower revenue for 2025, but reported sharply higher profit following a major divestment gain and said it expects oncology revenue growth in 2026. Read More

Hutchmed China shares rise as tumour treatment trial begins

4th Mar 2026 12:08

(Alliance News) - Hutchmed China Ltd on Wednesday said it had launched a Phase I/IIa clinical trial of its cancer treatment HMPL-A580. Read More

UK earnings, trading statements calendar - next 7 days

26th Feb 2026 14:45

Read More

Hutchmed China hails lung cancer trial results published in Lancet

14th Jan 2026 12:06

(Alliance News) - Hutchmed China Ltd on Wednesday said the results from its SACHI phase-three lung cancer trial have been published in medical journal the Lancet. Read More

Hutchmed China hails sovleplenib results for form of anaemia in China

7th Jan 2026 11:41

(Alliance News) - Hutchmed China Ltd on Wednesday announced topline results of a phase 3 trial of its selective small molecule inhibitor sovleplenib, in a form of anaemia. Read More

See more Hutchmed news
FTSE 100 Latest
Value10,284.75
Change-129.19

Login to your account

Forgot Password?

Not Registered